Evinature

Clinically proven, evidence-based nutraceuticals for gut health

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in April 2021 by Apan Amos Damri, Dr. Prof. Shomron Ben-Horin M.D., and Nir Salomon ChB, Evinature operates with 11–50 employees. The company has raised $6.5M across three funding rounds from one investor. In February 2024, Evinature secured a seed funding round.

Business overview

Evinature develops natural, evidence-based nutraceuticals for gut health, combining modern science with traditional botanical knowledge. The company offers well-researched solutions and personalized guidance based on individual wellness goals, supported by ongoing digital check-ins and optional clinic-based care. Evinature serves health-minded communities globally, focusing on the Health Tech & Life Sciences sector with products like CurQD® and DivertX, and operates across B2B, B2B2C, and B2C business models.

Strategic signal

In May 2024, Evinature's CurQD® trial was spotlighted at the CCF’s IBD Innovate Conference, highlighting the company's commitment to advancing research in inflammatory bowel disease (IBD). This signals strong scientific validation and growing recognition within the medical community for Evinature's innovative approach to IBD patient care.

Log in to access full profile

Company Intelligence Q&A

What is Evinature's primary focus in the healthcare sector?
Evinature focuses on developing and providing clinically proven, evidence-based nutraceuticals for gut health, particularly for conditions like Inflammatory Bowel Disease (IBD), Crohn's, and Colitis.
When was Evinature founded and by whom?
Evinature was founded in April 2021 by Apan Amos Damri, Dr. Prof. Shomron Ben-Horin M.D., and Nir Salomon ChB.
What was a significant development for Evinature in April 2024?
In April 2024, Evinature integrated its healthcare solutions across 35 US medical centers to streamline accessibility for IBD treatment.
Has Evinature's CurQD® protocol shown efficacy in pediatric trials?
Yes, in November 2024, Evinature's CurQD® was reported to be successful in a pediatric trial for reducing symptoms of IBD.
What was the total capital raised by Evinature?
Evinature has raised a total of $6.5M across three funding rounds.
Log in to access full profile